Evidence map›Paper›PMID 41440236›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety.

Büşra Bülbül, Bekir Ucun, Can Cangür, İrem Turgut Yeğen, Orhan Önder Eren, Cengiz Yılmaz, Gürkan Gül, Atike Pınar Erdoğan, Ece Şahin Hafızoğlu, Erhan Gökmen and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Büşra BülbülMedical Oncology Department Tıbbi Onkoloji, Medical Faculty, Selçuk University, Konya 42250, Turkey.ORCID 0000-0001-7922-0775
Bekir UcunMedical Oncology Department Tıbbi Onkoloji, Medical Faculty, Selçuk University, Konya 42250, Turkey.ORCID 0000-0002-5881-4395
Can CangürMedical Oncology Department Tıbbi Onkoloji, Medical Faculty, Selçuk University, Konya 42250, Turkey.ORCID 0009-0004-1400-0594
İrem Turgut YeğenMedical Oncology Department Tıbbi Onkoloji, Medical Faculty, Selçuk University, Konya 42250, Turkey.ORCID 0009-0002-3352-6802
Orhan Önder ErenMedical Oncology Department Tıbbi Onkoloji, Medical Faculty, Selçuk University, Konya 42250, Turkey.
Cengiz YılmazMedical Oncology, İzmir City Hospital, İzmir 35540, Turkey.ORCID 0000-0002-7861-5000
Gürkan GülMedical Oncology, İzmir City Hospital, İzmir 35540, Turkey.
Atike Pınar ErdoğanMedical Oncology Department, Medical Faculty, Manisa Celal Bayar University, Manisa 45030, Turkey.
Ece Şahin HafızoğluMedical Oncology Department, Medical Faculty, Manisa Celal Bayar University, Manisa 45030, Turkey.ORCID 0009-0007-7753-1482
Erhan GökmenMedical Oncology Department, Medical Faculty, Ege University, İzmir 35100, Turkey.ORCID 0000-0003-4596-2986
Oguzcan OzkanMedical Oncology Department, Medical Faculty, Ege University, İzmir 35100, Turkey.ORCID 0000-0002-4075-7775
Murat ArazMedical Oncology Department, Medical Faculty, Necmettin Erbakan University, Konya 42090, Turkey.ORCID 0000-0002-4632-9501
Ahmet OruçMedical Oncology Department, Medical Faculty, Necmettin Erbakan University, Konya 42090, Turkey.ORCID 0009-0003-0923-5148
Serkan YıldırımMedical Oncology Department Tıbbi Onkoloji, Medical Faculty, Selçuk University, Konya 42250, Turkey.ORCID 0000-0001-7998-1558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCDK4/6 inhibitors constitute standard first-line therapy for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). We investigated real-world predictors of overall survival (OS), with particular focus on high ER expression (≥90%).

methodsIn this multicenter, retrospective study, we analyzed 603 HR-positive/HER2-negative MBC patients treated with CDK4/6 inhibitors (ribociclib or palbociclib) between May 2020 and June 2024. We evaluated demographic, clinical, and pathological factors for their impact on OS using univariate and multivariate Cox regression analyses.

resultsIn univariate analysis, significantly longer OS was observed in endocrine therapy-naive patients (median OS: 51.0 vs. 33.3 months;

conclusionsOur study identifies treatment naivety and exceptionally high ER expression (≥90%) as key independent predictors of prolonged OS in CDK4/6 inhibitor-treated MBC patients. These findings underscore the importance of early CDK4/6 inhibitor implementation and suggest that quantitative ER assessment may refine patient selection beyond conventional positivity thresholds.

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsReceptors, EstrogenAdultAgedAged, 80 and overAminopyridinesFemaleHumansMiddle AgedNeoplasm MetastasisPiperazinesPurinesPyridinesAminopyridinesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6palbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesReceptors, Estrogenribociclibbiomarkerbreast cancerCDK4/6 inhibitorshigh ER expressionoestrogen receptoroverall survivalreal-world evidencetreatment naivety

Identifiers

PMID41440236
PMCPMC12732278

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.